showed a trendP = .06
In the subset of LCNEC patients treated with platinum-based chemotherapy ( n = 11), those harboring HR mutations ( n = 3) also showed a trend of longer PFS ( P = .06, Supplementary Fig.
In the subset of LCNEC patients treated with platinum-based chemotherapy ( n = 11), those harboring HR mutations ( n = 3) also showed a trend of longer PFS ( P = .06, Supplementary Fig.